Mallinckrodt Creditors Question Ch. 11 Drug Sale Process

Law360 (June 11, 2021, 10:12 PM EDT) -- The official committee of unsecured creditors in the Chapter 11 case of drugmaker Mallinckrodt PLC objected on Friday to the company's proposed sale of a development-stage pharmaceutical, saying the company didn't run an adequate marketing process and is seeking to sell the asset at too low of a price.

In the filing, the committee said Mallinckrodt's proposal to sell the assets related to VTS-270, a drug in late-stage clinical trials for the treatment of a rare neurodegenerative disease, came after a limited marketing process conducted by the debtor's employees and not by an investment banker.

The $1.75 million sale price included...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!